AstraZeneca boss urges 'Chinese speed' for western pharma
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pascal Soriot urged Western drugmakers to operate at "Chinese speed," warning that US and European pharmaceutical sectors risk being left behind by Chinese rivals investing heavily in antibody drug conjugates and cell therapy.
- AstraZeneca reported H1 2026 revenues of £30.7bn, a 6% increase year-on-year at constant exchange rates, and reaffirmed its target of $80bn in annual sales by 2030, up from $59bn last year.
- Soriot acknowledged the surprise clinical trial failure of Wainua, a key heart disease drug candidate, but said AstraZeneca's overall drug pipeline remained "unmatched."
- Soriot dismissed fears that AI would eliminate pharma jobs, calling it "a bit of a fake story" and saying AI tools make him "faster and smarter" in areas like trial protocol design.
- AstraZeneca plans to engage with new UK government leader Andy Burnham to seek clarity on a US-UK drug pricing deal struck under Trump's tariff threats, which analysis suggests could cause 229,000 excess deaths in England.
- Soriot drew a direct parallel to the automotive industry, noting that Western carmakers' focus on petrol engines allowed Chinese companies to dominate electric vehicle and battery sales.
Why it matters: The highest-paid FTSE 100 CEO is publicly framing Chinese competition as an existential threat to Western pharma — not in five years, but now — while his own company just posted 6% revenue growth and is racing to plug a pipeline gap left by the Wainua failure. The simultaneous pivot to AI productivity and to lobbying the new UK government on a tariff-driven deal shows AstraZeneca is simultaneously defending its growth story on three fronts: speed, science, and politics.
